Arcus Biosciences (RCUS) Cash & Equivalents (2016 - 2026)

Arcus Biosciences' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $201.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 4.69% year-over-year to $201.0 million; the TTM figure through Mar 2026 stood at $201.0 million (up 4.69% YoY), while the FY2025 annual figure was $222.0 million, up 48.0% from the prior year.
• Cash & Equivalents was $201.0 million for Q1 2026 at Arcus Biosciences, down from $222.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $549.0 million in Q1 2022 to a low of $127.0 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $224.6 million across 5 years, with a median of $206.0 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents sank 56.65% in 2023, then jumped 58.97% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $206.0 million in 2022, then sank by 38.35% to $127.0 million in 2023, then rose by 18.11% to $150.0 million in 2024, then soared by 48.0% to $222.0 million in 2025, then slipped by 9.46% to $201.0 million in 2026.
• The last three Cash & Equivalents figures came in at $201.0 million (Q1 2026), $222.0 million (Q4 2025), and $238.0 million (Q3 2025), per Business Quant data.